#Denmark #Lundbeck #Valby #Migraine #Vyepti

Lundbeck's Phase IV THRIVE Trial Results

H. Lundbeck A/S recently disclosed significant outcomes from its Phase IV open-label THRIVE trial, which evaluated VYEPTI® (eptinezumab) for treating adults suffering from migraine who experienced insufficient relief from prior therapies targeting calcitonin gene-related peptide (CGRP). This study serves as a pivotal step in enhancing treatment options for individuals who continue to face substantial migraine challenges despite existing preventive medications.

Overview of the THRIVE Trial

The THRIVE trial (NCT06701526) focused on adults with migraine who had shown inadequate responses to previous CGRP-targeting preventive treatments. Conducted as a multicenter study across various locations in the United States, the THRIVE trial was designed to fill a crucial gap in clinical evidence regarding treatment sequencing for migraine patients.

In the trial, participants initially received a 100 mg infusion of eptinezumab, with a dose escalation to 300 mg at the 12-week mark. Remarkably, by week 24, the trial's primary endpoint was achieved, where 60% of the participants reported being 'much improved' or 'very much improved' according to the Patient Global Impression of Change (PGIC) assessment. Furthermore, at the 12-week checkpoint, 44% of participants indicated significant improvement.

Tarek Samad, Lundbeck’s Executive Vice President and Head of Research and Development, stated that these findings represent critical clinical trial data for patients enduring significant migraine burdens. He emphasized the importance of addressing what treatment options may entail following failed responses to existing therapies.

Impact on Migraine Patients

Migraine is a complex neurological condition marked by recurrent, debilitating headaches often accompanied by nausea, light sensitivity, and vomiting. It can severely disrupt daily activities, negatively impacting work productivity and personal relationships. With migraine being one of the most prevalent neurological disorders worldwide, it stands as a leading cause of disability, especially for those under 50 years of age.

The THRIVE trial findings underscore the challenges faced by patients experiencing high burdens of migraine, even after the introduction of novel preventive therapies. Real-world studies indicate considerable discontinuation rates for anti-CGRP monoclonal antibodies, reaching approximately 40-45%, primarily due to inadequate effectiveness in managing symptoms.

Safety and Tolerability of Eptinezumab

Throughout the trial, eptinezumab was well-tolerated among participants, with no new safety concerns identified. Safety evaluations were conducted by monitoring adverse events and vital signs consistently. Eptinezumab’s safety profile has been established in prior clinical trials involving over 2,000 patients, with common adverse reactions including nasopharyngitis and hypersensitivity.

The data collected from the THRIVE trial will be crucial for guiding future treatment protocols and will be presented at upcoming scientific congresses, fulfilling the broader aim of enhancing the lives of those living with migraines through better treatment solutions.

Conclusion

As Lundbeck continues to innovate in brain health, the promising results from the THRIVE trial serve as a beacon of hope for many migraine patients who have seen limited effectiveness from past treatments. The evidence supporting eptinezumab for migraine prevention continues to grow, reflecting Lundbeck’s commitment to addressing the needs of individuals facing debilitating neurological conditions.

With VYEPTI® being approved in several markets and expanding accessibility, there is optimism surrounding advancements in migraine management, paving the way for more effective patient care and improved quality of life.